HIV in the Time of COVID-19: The Case for Investment

January 28, 2022 gilead

SOURCE: Gilead Sciences

DESCRIPTION:

As the world continues to grapple with COVID-19, we can’t lose sight of another health crisis: the ongoing HIV epidemic. In this Gilead-created policy paper, read about the critical role that continued investment in HIV can play in supporting public health and achieving our shared goal of ending the epidemic by 2030.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

Originally published by Gilead Sciences

Tweet me: As the world continues to grapple with COVID-19, @GileadSciences reminds us that we can’t lose sight of another health crisis: the ongoing HIV epidemic. https://bit.ly/3rOubxc

KEYWORDS: NYSE:GILD, Gilead Sciences, HIV

"HIV in the Time of Covid-19: The Case for Investment" infographic

Read more...

Previous Article
The Home Depot Names Ted Decker CEO, Effective March 1, 2022
The Home Depot Names Ted Decker CEO, Effective March 1, 2022

Craig Menear Continues as Chair of the Board SOURCE: The Home Depot DESCRIPTION:ATLANTA, January 28, 2022 /...

Next Article
Why Work at Acre? - EU

SOURCE: Acre DESCRIPTION:By Grace Coleman ​Acre will be raising a toast this month to celebrate its second ...

×

Don’t Miss a Thing
Get sustainable procurement news from around the world straight to your inbox

Subscribe →

First Name
Last Name
Opt in to receive more information from EcoVadis
Thank you!
Error - something went wrong!